Leerink Swann Starts Neurocrine Bio. (NBIX) at Outperform; Threading the Needle in Women's Health
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $152.57 -0.24%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Leerink Swann initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with an Outperform.
Leeink analyst said, "NBIX has two attractive assets that both represent the company's ability to "thread the needle" in targeting therapeutic windows for known targets to open previously untapped commercial opportunities. We believe regulatory and commercial success is likely with these agents and expect NBIX shares to appreciate as additional data accrue on these programs. Our valuation is based on a risk-adjusted DCF analysis that assumes surpassable projections for both products in the U.S."
For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.
Shares of Neurocrine Bio. closed at $7.74 yesterday.
Leeink analyst said, "NBIX has two attractive assets that both represent the company's ability to "thread the needle" in targeting therapeutic windows for known targets to open previously untapped commercial opportunities. We believe regulatory and commercial success is likely with these agents and expect NBIX shares to appreciate as additional data accrue on these programs. Our valuation is based on a risk-adjusted DCF analysis that assumes surpassable projections for both products in the U.S."
For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.
Shares of Neurocrine Bio. closed at $7.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- TD Cowen Assumes Cabaletta Bio (CABA) at Buy
- TD Cowen Assumes Nektar Therapeutics (NKTR) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
